Applied DNA Sciences (APDN) Tops Q4 EPS by 7c

Applied DNA Sciences (NASDAQ: APDN) reported Q4 EPS of ($0.02), $0.07 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $4 million versus the consensus estimate of $2.09 million.

Excluding non-cash expenses, Adjusted EBITDA for the quarter ended September 30, 2015 was positive $213 thousand compared to a negative Adjusted EBITDA of $2.4 million for the same quarter last year and a negative Adjusted EBITDA of $478 thousand in the prior fiscal quarter. The improvement in Adjusted EBITDA is primarily related to the increased revenues achieved for the quarter ended September 30, 2015.

For earnings history and earnings-related data on Applied DNA Sciences (APDN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c